| Literature DB >> 32661925 |
Hongyu Li1,2, Zeming Wu3,2, Xiaoqian Liu3,4, Sheng Zhang1,2, Qianzhao Ji5,2, Xiaoyu Jiang5,2, Zunpeng Liu3,2, Si Wang5,2, Jing Qu3,4,2, Weiqi Zhang1,4,2,6, Moshi Song7,8,9, Eli Song10,11, Guang-Hui Liu12,13,14,15,16.
Abstract
Entities:
Mesh:
Substances:
Year: 2020 PMID: 32661925 PMCID: PMC7452965 DOI: 10.1007/s13238-020-00744-4
Source DB: PubMed Journal: Protein Cell ISSN: 1674-800X Impact factor: 14.870
Figure 1Generation and phenotypic analyses of hESCs, hMSCs and hVSMCs. (A) Schematic diagram of the generation of ALKBH1-deficient hESCs and derived hMSCs and hVSMCs. (B) Illustration of ALKBH1-targeting strategy by CRISPR/Cas9-mediated non-homologous end-joining (NHEJ). (C) Western blotting analysis of ALKBH1 in ALKBH1+/+ and ALKBH1−/− hESCs. β-Tubulin was used as a loading control. (D) Immunostaining of pluripotency markers including NANOG, SOX2 and OCT4 in ALKBH1+/+ and ALKBH1−/− hESCs. Scale bar, 50 μm. (E) Karyotyping analysis of ALKBH1−/− hESCs. (F) FACS analysis of the MSC-specific surface markers CD73, CD90 and CD105 in ALKBH1+/+ and ALKBH1−/− hMSCs. (G) Western blotting analysis of ALKBH1 in ALKBH1+/+ and ALKBH1−/− hMSCs. β-Tubulin was used as a loading control. (H) Top, representative track showing the mRNA abundance of ALKBH1 in ALKBH1+/+ and ALKBH1−/− hMSCs. Bottom, sgRNA targeting site for ALKBH1 (exon 1) and its flanking region are zoomed. (I) Growth curve analysis of ALKBH1+/+ and ALKBH1−/− hMSCs. Data are presented as the mean ± SEM. n = 3. (J) SA-β-Gal staining of ALKBH1+/+ and ALKBH1−/− hMSCs at passage 10. Scale bar, 100 μm. Data are presented as the mean ± SEM. n = 3. ***, P < 0.001. (K) Clonal expansion analysis of ALKBH1+/+ and ALKBH1−/− hMSCs at passage 10. Data are presented as the mean ± SEM. n = 3. ***, P < 0.001. (L) Heatmap showing the relative expression levels of genes associated with cell proliferation in ALKBH1+/+ and ALKBH1−/− hMSCs. (M) Heatmap showing the relative expression levels of genes associated with SASP in ALKBH1+/+ and ALKBH1−/− hMSCs. (N) FACS analysis of the JC-10 staining in ALKBH1+/+ and ALKBH1 hMSCs at passage 3. Data are presented as the mean ± SEM. n = 3. *, P < 0.05. (O) Immunostaining of VSMC-specific markers Calponin and SM22α in ALKBH1+/+ and ALKBH1−/− hVSMCs. Scale bar, 25 μm. (P) Western blotting analysis of ALKBH1 in ALKBH1+/+ and ALKBH1−/− hVSMCs. β-Tubulin was used as a loading control. (Q) FACS analysis of apoptotic cells by Annexin-V and propidium iodide (PI) labeling in ALKBH1+/+ and ALKBH1−/− hVSMCs. Data are presented as the mean ± SEM. n = 3. ***, P < 0.001. (R) Wound healing assay for the analysis of migration ability of ALKBH1+/+ and ALKBH1−/− hVSMCs. Scale bar, 100 μm. Data are presented as the mean ± SEM. n = 4. *, P < 0.05; **, P < 0.01
Figure 2Detection of 6mA levels in hESCs, hMSCs and hVSMCs. (A) Dot blotting showing 6mA in ALKBH1+/+ and ALKBH1−/− hMSCs. Data are presented as the mean ± SEM. n = 3. ns, not significant. (B) Schematic representation of quantification of 6mA in gDNA by LC-MS/MS. (C–E) Quantification of 6mA in gDNA by LC-MS/MS in ALKBH1+/+ and ALKBH1−/− hESCs (C), hMSCs (D) and hVSMCs (E). Data are presented as the mean ± SEM. n = 3. ns, not significant. (F) Whole genome analysis of mycoplasma, bacteria and fungi contaminations in ALKBH1+/+ and ALKBH1−/− hMSCs. Mycoplasma is represented by Mycoplasma genitalium (M. genitalium) and Mycoplasma hyorhinis (M. hyorhinis). Bacteria is represented by Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli). Fungi is represented by Aspergillus fumigatus (A. fumigatus). (G) Quantification of 6mA in gDNA and a negative control (ddH2O instead of gDNA) by LC-MS/MS. (H) Schematic graph showing the major effects of ALKBH1 deficiency on the homeostatic maintenance in hESCs, hMSCs and hVSMCs